Emiliano Calvo

Research interests

Publications

• Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

  New England Journal of Medicine · 2025 · https://doi.org/10.1056/nejmoa2405008

• MYC targeting by OMO-103 in solid tumors: a phase 1 trial

  Nature Medicine · 2024 · https://doi.org/10.1038/s41591-024-02805-1

• Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

  Nature · 2024 · https://doi.org/10.1038/s41586-024-08305-z

• Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.09.158

• Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors

  Cancer Discovery · 2022 · https://doi.org/10.1158/2159-8290.cd-21-1345

• Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

  Journal for ImmunoTherapy of Cancer · 2021 · https://doi.org/10.1136/jitc-2020-002068

• Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

  Clinical Cancer Research · 2019 · https://doi.org/10.1158/1078-0432.ccr-18-2740

• Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort

  Journal of Thoracic Oncology · 2019 · https://doi.org/10.1016/j.jtho.2019.10.004

• Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

  Clinical Cancer Research · 2019 · https://doi.org/10.1158/1078-0432.ccr-18-3334

• HER kinase inhibition in patients with HER2- and HER3-mutant cancers

  Nature · 2018 · https://doi.org/10.1038/nature25475

• CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.76.6212

• Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

  Cancer Cell · 2018 · https://doi.org/10.1016/j.ccell.2018.04.001

• Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30496-x

• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30098-5

• Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2014.60.7341

• Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.14.5482

Current projects

No projects listed.